FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to a liquid pharmaceutical composition containing Glu-plasminogen or biologically active mutant Glu-plasminogen polypeptide, having at least 80 % amino acid sequence identity with native Glu-plasminogen polypeptide in concentration of 0.01 mg/ml to 80 mg/ml; a tonicity modifier which is sodium chloride in concentration of 30 mM to 100 mM, which enables to achieve osmolality of composition from 180 mOsm to 350 mOsm; and a stabilizer which is arginine or glycine, in concentration of 10 mM to 100 mM; and wherein the pH of the composition ranges from 5.0 to 8.0, also relates to use of the pharmaceutical composition.
EFFECT: group of inventions provides producing a pharmaceutical composition of Glu-plasminogen with improved stability.
21 cl, 22 dwg, 17 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
| STABLE AQUEOUS PROTEIN COMPOSITIONS OF MIA/CD-RAP | 2011 |
|
RU2739078C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
| PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2775944C2 |
| PHARMACEUTICAL COMPOSITION OF FUSION PROTEIN TACI-FC | 2020 |
|
RU2779387C1 |
| COMPOSITIONS OF ANTIBODIES TO RSV AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2807524C2 |
| CONFORMATIONALLY RESTRICTED PEPTIDES | 2020 |
|
RU2838107C2 |
| ARGININE DEIMINASE ENCAPSULATED IN ERYTHROCYTES, AND THEIR USE IN TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY | 2018 |
|
RU2773220C2 |
| PULMONARY SURFACTANT COMPOSITIONS AND METHODS OF USING THEM PROMOTING MUCUS ELIMINATION | 2007 |
|
RU2455021C2 |
| FORMULATIONS OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOGUES | 2019 |
|
RU2833459C2 |
